Our orthotopic coinjection experiments with control or NID2 knockdown CAFs with cancer cells reveal that NID2 targeting can reduce primary tumor growth (with chemotherapy treatment) and reduce metastatic burden in the liver, leading to improvements in median survival. Here, NID2 is linked to cancer.